Dr Dmitry Karayev Md is categorized under Internal Medicine Practitioners in Los Angeles, CA and active since 2013.
Dr Dmitry Karayev Md was established in 2013, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Internal Medicine Practitioners business, which does work in the B2C market, and is classified as a Internal Medicine Practitioners, under code number 621111 by the NAICS.
If you are seeking more information, feel free to contact Dmitry Karayev at the company’s single location by writing to 8700 Beverly Boulevard, Los Angeles, California CA 90048 or by phoning (310) 423-5897. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Dr Dmitry Karayev Md |
| Contact Person: | Dmitry Karayev |
| Address: | 8700 Beverly Boulevard, Los Angeles, California 90048 |
| Phone Number: | (310) 423-5897 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2013 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2C (Business to Consumer) |
| Business Category: | Internal Medicine Practitioners |
| SIC Code: | 8011 |
| NAICS Code: | 621111 |
| Share This Business: |
Dr Dmitry Karayev Md was started in 2013 to provide professional Internal Medicine Practitioners under the SIC code 8011 and NAICS code 621111. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Dmitry Karayev for inquiries that concern Dr Dmitry Karayev Md by calling the company number (310) 423-5897, as your correspondence is most welcome. Additionally, the physical location of the single location of Dr Dmitry Karayev Md can be found at the coordinates 34.076703,-118.38057 as well as the street address 8700 Beverly Boulevard in Los Angeles, California 90048.
For its online presence, you may visit Dr Dmitry Karayev Md’s website at and engage with its social media outlets through on Twitter and on Facebook.